Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
2002 2
2005 1
2009 2
2011 1
2012 1
2013 5
2014 2
2015 4
2016 2
2017 2
2018 4
2019 4
2020 3
2021 1
2022 3
2023 2

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Acid Suppressants on Non-Helicobacter pylori Helicobacters Within Parietal Cells.
Nakamura M, Murasato F, Øverby A, Kodama Y, Michimae H, Sasaki K, Flahou B, Haesebrouck F, Murayama SY, Takahashi S, Uchida M, Suzuki H, Matsui H. Nakamura M, et al. Among authors: michimae h. Front Pharmacol. 2022 Jul 22;13:692437. doi: 10.3389/fphar.2022.692437. eCollection 2022. Front Pharmacol. 2022. PMID: 35935877 Free PMC article.
Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067).
Matoda M, Takeshima N, Michimae H, Iwata T, Yokota H, Torii Y, Yamamoto Y, Takehara K, Nishio S, Takano H, Mizuno M, Takahashi Y, Takei Y, Hasegawa T, Mikami M, Enomoto T, Aoki D, Sugiyama T. Matoda M, et al. Among authors: michimae h. Gynecol Oncol. 2018 Jun;149(3):513-519. doi: 10.1016/j.ygyno.2018.04.009. Epub 2018 Apr 13. Gynecol Oncol. 2018. PMID: 29661497 Clinical Trial.
A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09).
Kawabata R, Izawa N, Suzuki T, Nagahisa Y, Nishikawa K, Takahashi M, Nakamura M, Ishiguro A, Katsuya H, Hihara J, Manaka D, Negoro Y, Tsuji A, Takahashi T, Kochi M, Azuma M, Kadowaki S, Michimae H, Sunakawa Y, Ichikawa W, Fujii M. Kawabata R, et al. Among authors: michimae h. Target Oncol. 2023 May;18(3):359-368. doi: 10.1007/s11523-023-00961-x. Epub 2023 Apr 15. Target Oncol. 2023. PMID: 37060430 Clinical Trial.
Chemotherapy versus best supportive care in advanced lung cancer and idiopathic interstitial pneumonias: A retrospective multi-centre cohort study.
Miyamoto A, Michimae H, Nakahara Y, Akagawa S, Nakagawa K, Minegishi Y, Ogura T, Hontsu S, Date H, Takahashi K, Homma S, Kishi K; Investigators Group for Lung Cancer and IIP. Miyamoto A, et al. Among authors: michimae h. Respir Investig. 2023 Mar;61(2):284-295. doi: 10.1016/j.resinv.2022.10.009. Epub 2022 Dec 7. Respir Investig. 2023. PMID: 36496345 Free article.
A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.
Yonemori K, Shimomura A, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hashimoto J, Yamamoto H, Hirakawa A, Michimae H, Hamada A, Yoshida T, Sukigara T, Tamura K, Fujiwara Y. Yonemori K, et al. Among authors: michimae h. Eur J Cancer. 2019 Mar;109:84-91. doi: 10.1016/j.ejca.2018.11.014. Epub 2019 Jan 28. Eur J Cancer. 2019. PMID: 30703739 Clinical Trial.
The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1).
Murakami R, Matsumura N, Michimae H, Tanabe H, Yunokawa M, Iwase H, Sasagawa M, Nakamura T, Tokuyama O, Takano M, Sugiyama T, Sawasaki T, Isonishi S, Takehara K, Nakai H, Okamoto A, Mandai M, Konishi I. Murakami R, et al. Among authors: michimae h. Gynecol Oncol. 2019 May;153(2):312-319. doi: 10.1016/j.ygyno.2019.02.010. Epub 2019 Mar 8. Gynecol Oncol. 2019. PMID: 30853361 Clinical Trial.
Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m² versus 40 mg/m² in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial.
Motohashi T, Yabuno A, Michimae H, Ohishi T, Nonaka M, Takano M, Nishio S, Fujiwara H, Fujiwara K, Kondo E, Sugiyama T, Tabata T. Motohashi T, et al. Among authors: michimae h. J Gynecol Oncol. 2021 Jan;32(1):e9. doi: 10.3802/jgo.2021.32.e9. Epub 2020 Nov 10. J Gynecol Oncol. 2021. PMID: 33185050 Free PMC article. Clinical Trial.
35 results